Celldex Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
CLDX$31.24+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
As of December 31, 2025, our significant leased properties are described below.
| · · · · · · | |||
|---|---|---|---|
| · · Approximate · · · · | |||
| Property Location · · Square Feet · · Use · · Lease Expiration Date | |||
| Hampton, New Jersey | 33,400 | Headquarters, Office and Laboratory | July 2027(1) |
| Fall River, Massachusetts | 36,300 | Manufacturing, Office and Laboratory | July 2027(2) |
| New Haven, Connecticut | 17,700 | Office and Laboratory | October 2026(3) |
| (1) | Lease includes two renewal options of two years. |
| (2) | Lease includes one renewal option of three years. |
| (3) | In September 2025, we signed a new lease in New Haven, Connecticut to which we will relocate our existing New Haven operations to in 2026. The lease covers approximately 40,400 square feet of office and laboratory space and is scheduled to commence in 2026. The initial lease term is 5.5 years with three renewal options of five years each. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.